AMAG Pharmaceuticals, Inc.
|$508 M||Market Cap|
|11.3%||EBIT / EV|
|8.0%||FCF / EV|
|105.8%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|The EBIT / Enterprise Value of 11.3% ranks as Very High.|
|The Free Cash Flow / Enterprise Value of 8.0% ranks as Very High.|
|The Return on Invested Capital Value of 8.4% ranks as Below Average.|
|The Cash Return on Capital Value of 5.9% ranks as Below Average.|
|The 3 Year Average Revenue Growth Value of 105.8% ranks as Very High.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 1.59.|
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company's products includes Intrarosa, Makena, CBR, Feraheme, and MuGard. AMAG Pharmaceuticals was founded on 9th, November 1981 and is headquartered in Waltham, MA.
|Valvoline Inc. (VVV)|
|Procter & Gamble Company (PG)|
|McDonald's Corporation (MCD)|
|Fiat Chrysler Automobiles N.V. (FCAU)|
|Baozun Inc Sponsored ADR Class A (BZUN)|
|Vector Group Ltd. (VGR)|
|New Stocks Added!|